In the life-critical exploration of anticancer drug development, the success or failure of clinical trials largely depends on the scientific rigor and foresight of their statistical strategies. As a g...
A conversation with Ms. Ying Xiaowei, EVP of GCP ClinPlus, on how US biotech companies can utilize China as a strategic accelerator for their global development plans.Q: What is the strategic value fo...
— Insights from China’s rapidly evolving next-generation cell therapy fieldIn Vivo CAR-T—directly delivering CAR genes into the human body to engineer immune cells in situ—is emerging as one of th...
